Adebrelimab: a PD-L1 that "doesn't rely on standing out on its own" — how Hengrui uses it to thicken its portfolio

Adebrelimab is a recombinant humanized IgG4 anti-PD-L1 monoclonal antibody developed in-house by Hengrui. Its mechanism holds no suspense: it blocks the binding of PD-L1 on tumor cells to PD-1 on T cells, releasing the immune "brake" so T cells can recognize and attack the tumor again. This pathway has been validated repeatedly over the past decade, meaning there is almost no risk of mechanistic failure — but also no first-mover mechanistic dividend at all.

In March 2023, the NMPA announced approval of adebrelimab (filed by Hengrui's subsidiary Suncadia) in combination with chemotherapy as first-line treatment for extensive-stage small cell lung cancer (ES-SCLC). This was its first ID card, and Hengrui's second immune checkpoint inhibitor after camrelizumab (PD-1, AiRuiKa^®).

How deep is Hengrui's oncology portfolio? Besides the two immune checkpoint inhibitors, there is the anti-angiogenic apatinib (Aitan^®), the HER2-pathway drug pyrotinib, and a whole rising pipeline of antibody–drug conjugates (ADCs) — multiple ADCs targeting HER2, Claudin18.2 and Nectin-4 have already entered the clinic. Understanding this is key: adebrelimab has never been an isolated single product; it is the "immune foundation" of this portfolio, its fate is determined by the portfolio, and only within the portfolio can it be valued correctly.

Supporting its first approval was the CAPSTONE-1 study (i.e. SHR-1316-III-301) — a randomized, double-blind, placebo-controlled multicenter trial led by Professors Cheng Ying, Wang Jie and others, published in The Lancet Oncology. Core data:

These are genuinely positive data: it hit the hardest endpoint, overall survival, pushing median survival above 15 months in extensive-stage small cell lung cancer, a tumor type that had "stagnated in treatment for thirty years".

But the next point is equally important: the 15.3-month figure cannot be used to claim it is stronger than its peers. In the same indication, the overall survival hazard ratios of Roche's atezolizumab (IMpower133), AstraZeneca's durvalumab (CASPIAN) and Henlius's serplulimab (ASTRUM-005) fall in the range of 0.70, 0.73 and 0.63 respectively — adebrelimab's 0.72 lands squarely in the middle, neither at the bottom nor standing out. These are results from different trials with different enrolled populations; cross-trial number comparisons are marketing talk, not evidence. If anything, on best-in-class, serplulimab's 0.63 is more striking.

Adebrelimab took a purely "China-first" registration route: from early exploration to pivotal trials everything was done domestically, with no reliance on a Chinese subgroup of global multicenter data, thereby avoiding the hassle of ethnic bridging and cross-border data recognition. For a large pharma like Hengrui, well versed in communicating with CDE, this road carries very high certainty.

What really deserves attention is its "move to earlier lines" — extending from advanced disease to curative-intent settings. On June 25, 2026, Hengrui announced that its new perioperative non-small cell lung cancer indication (based on the SHR-1316-III-303 study) had been approved, making it the first domestic PD-L1 inhibitor approved for perioperative NSCLC in China. The regimen is platinum-based chemotherapy plus adebrelimab as neoadjuvant therapy, followed by adebrelimab monotherapy as adjuvant therapy, for resectable stage II, IIIA and IIIB EGFR/ALK-negative patients; the study covered 58 centers nationwide and enrolled 501 patients, with Professor Wu Yilong as principal investigator.

And this time the data are not "ordinary". Combining the oral presentation at the 2026 American Association for Cancer Research (AACR) Annual Meeting and Hengrui's approval announcement: major pathological response rate 53.8% (nearly three times the control arm), pathological complete response rate 31.1% (7.6% in control), 2-year event-free survival 74.8%, a significant 48% reduction in the risk of recurrence, progression or death (hazard ratio about 0.52), and a surgery rate as high as 88.8%; both primary endpoints (pathological response and event-free survival) achieved statistically significant and clinically meaningful improvements with good safety. An event-free survival hazard ratio pushed down to 0.52 and nearly 90% of patients successfully undergoing surgery — this is a solid perioperative dataset, no worse than peers. In the perioperative line, adebrelimab is "late in time, but top of the class in data". (Overall survival data are not yet mature; the announcement did not disclose an OS hazard ratio.)

The perioperative setting is currently the hottest battlefield in lung cancer immunotherapy, because it points to "cure" rather than "life extension", and the potential population is larger (about 150,000 driver-negative resectable patients). Strong as the data are, in terms of timing adebrelimab is still clearly a latecomer here:

Durvalumab deserves particular vigilance: its perioperative label based on the AEGEAN study (in China, resectable stage IIA–IIIB) overlaps heavily with adebrelimab's population (resectable stage II, IIIA and IIIB, EGFR/ALK-negative), yet it was approved about 15 months earlier; Junshi's toripalimab (PD-1) was more than two years earlier still. The same is true at the other end of small cell lung cancer — in limited-stage small cell lung cancer (LS-SCLC), durvalumab was approved in China in June 2025 on the ADRIATIC study, flying the banner of "first and only"; adebrelimab is still in the clinic in this line and, entering later, can only be an imitator.

String the three lines together and the conclusion is clear: in extensive-stage small cell lung cancer, limited-stage small cell lung cancer and perioperative non-small cell lung cancer, adebrelimab is a fast follower in every case. This is not disparagement but the precondition for understanding its strategic value — its value has never been in "being first to launch".

Looking only at the molecule itself, adebrelimab is unremarkable. But put it back into Hengrui's huge commercial machine, and the logic is completely different. This is exactly where large domestic pharma differs from biotech: the same fast follower might be a burden in the hands of a small company without channels, but in Hengrui's hands it is a volume opportunity at almost "zero incremental cost".

The first lever is reuse of the commercial network. Hengrui's oncology sales team already covers leading thoracic, lung cancer and GI centers nationwide, where camrelizumab, apatinib and pyrotinib are prescribed daily. Adebrelimab enters the same departments, faces the same physicians and goes through the same hospital access processes, with almost no need to build a new team. The most expensive "hospital listing" and "education" costs of a new PD-L1 are diluted here by the existing platform to nearly zero.

The second lever, more hidden and more important, is the portfolio economics of an "in-house immune foundation". When Hengrui wants to combine its ADCs and anti-angiogenic drugs with an immune checkpoint inhibitor — for example the ongoing "adebrelimab + Claudin18.2 ADC + chemotherapy" for advanced solid tumors, or immunotherapy plus radiotherapy for small cell lung cancer — it can use its own adebrelimab directly as the immune backbone, without having to buy from, negotiate with or share revenue with MSD (Keytruda) or Roche (Tecentriq). Owning its own PD-L1 means owning the pricing power, pacing power and data ownership of every combination regimen. This is the real reason Hengrui keeps this "ordinary" antibody.

The third is differentiated choice of tumor types. Hengrui did not have adebrelimab charge head-on into the most crowded advanced first-line non-small cell lung cancer, but first gained a foothold in small cell lung cancer, where immunotherapy had long been absent and unmet need was most rigid, then used its in-house backbone to spill over into esophageal squamous cell carcinoma, cervical cancer and perioperative settings. This is a pragmatic route of "find the soft spot first, then spread out".

Lung cancer is China's largest single oncology lane — according to data cited in the National Health Commission's 2024 screening plan, China had about 1.06 million new lung cancer cases and about 730,000 deaths in 2022. Adebrelimab has a foothold at both ends, but its situations are completely different.

At the small cell end, it stands relatively firm. Small cell lung cancer accounts for about 15% of lung cancer, and about 70% of patients are extensive-stage at diagnosis, with high malignancy and rapid relapse. This tumor type has no driver genes such as EGFR or ALK to target; for decades chemotherapy was the only pillar, and immunotherapy is a rare real breakthrough. Adebrelimab does not rely on PD-L1 expression stratification and is given to all comers — which actually becomes an accessibility advantage: primary-level hospitals can use it without companion diagnostic testing, with no testing threshold to clear. As the first domestic PD-L1 in this tumor type, it holds a good position in the import-substitution narrative. More rarely, it stands the test of time: the roughly six-year follow-up published at ELCC 2026 shows a persistent overall survival benefit, with five- and six-year survival rates more than double those of the control arm; such "long tail" long-term survival evidence is especially scarce in a tumor type where the vast majority of patients don't survive two years, and is its hardest trump card at the small cell end.

At the non-small cell end, it is a hard fight — solid data but late timing. The perioperative indication is restricted to the EGFR/ALK-negative population. A common misreading needs correcting here: the EGFR mutation rate in Chinese "non-squamous/adenocarcinoma" NSCLC is indeed as high as 45%–50%, but it cannot be applied to all NSCLC — the enrolled population in adebrelimab's perioperative study was predominantly squamous cell lung cancer (about 80%), and the EGFR mutation rate in squamous cell carcinoma is inherently low. So the "EGFR/ALK-negative" restriction, in this squamous-dominated perioperative population, excludes some non-squamous/adenocarcinoma patients but is nowhere near as dramatic as "cutting it in half". The real pressure is not the population but timing: durvalumab, toripalimab and nivolumab all arrived one to two years earlier, and this line is destined to be a positional battle fought as a peer, relying on data quality and Hengrui's channels rather than first-mover advantage.

Fortunately, at both ends adebrelimab has endorsement from top investigators (Professor Wu Yilong led the pivotal study), top-journal data (small cell in The Lancet Oncology, neoadjuvant esophageal squamous cell carcinoma in Nature Medicine) and a place in CSCO guidelines. Solid soft power is what gives it the confidence to maintain prescribing inertia in a red ocean.

Its extension into esophageal squamous cell carcinoma is also worth mentioning. China has a high incidence of esophageal squamous cell carcinoma, and the need for immunotherapy in this tumor type is equally real. An early study of adebrelimab monotherapy as neoadjuvant treatment for locally advanced resectable esophageal squamous cell carcinoma (NAITON-1907) was published in Nature Medicine, providing high-quality translational and efficacy evidence for its expansion into upper GI tumors. The logic of this line is the same as in lung cancer: use the same in-house immune backbone to cover tumor types that are high-incidence in China, with rigid demand, and that can synergize with Hengrui's existing GI commercial network. This "one foundation, spilling over into multiple tumor types" playbook is a typical way for large pharma to dilute single-product development costs through the portfolio.

But one must also be clear-eyed: every additional line brings another group of peer competitors. In esophageal squamous cell carcinoma there is camrelizumab itself (Hengrui's PD-1 is already a leading product in ESCC) and a forest of other domestic PD-1s; combination explorations in cervical cancer and solid tumors are also not short of rivals. Breadth of indications is easy to achieve, but the return from each line will be diluted by peers — this is where the "spread across many lines" narrative behind adebrelimab must be discounted.

Adebrelimab is a standard intravenous monoclonal antibody (600 mg/vial). Hengrui has a large-scale, mature antibody manufacturing system that already supports commercial supply of several antibodies including camrelizumab, with very low process scale-up risk, almost no reliance on external contract manufacturing, and assured supply continuity across multiple sites. In other words, along the chain of "molecule – clinical – regulatory – manufacturing – commercial", manufacturing is precisely adebrelimab's most stable segment.

What really weighs on margins is not manufacturing cost but price. After multiple rounds of NRDL negotiation, the annual treatment cost of domestic PD-1/PD-L1s has been pushed down to the RMB 10,000 level. The manufacturing cost share of an antibody itself, about 15%–25%, is not high, but when the selling price is dragged down by the price war, margin room is significantly compressed — the common fate of all domestic immune checkpoint inhibitors, and adebrelimab is no exception.

Pulling the view out to Hengrui's whole portfolio, adebrelimab's positioning requires honestly facing two facts.

First, it is a "foundation-type routine asset", not a "star-type priority asset". The center of gravity of Hengrui's oncology resources is clearly tilting toward next-generation assets — multiple ADCs, bispecifics and, in metabolism, GLP-1s are the current protagonists for attracting capital and telling stories. Adebrelimab looks more like a piece of the puzzle that is "marketed, stable and serves as a combination foundation", able to contribute steady cash flow and portfolio synergy, but unlikely to receive further "all-in" level investment. This means its indication expansion will be carefully budgeted rather than spread without limit.

One more realistic judgment on globalization: PD-L1s are completely commoditized globally, and the window for single-agent export has essentially closed. Hengrui's biggest out-licensing deals — licensing its GLP-1 assets to Kailera, the multi-program strategic alliance with GSK — do not include adebrelimab. This is not an oversight but a clear-headed trade-off: adebrelimab has no independent global registration path; its global value is at most that of a "built-in immune partner" when Hengrui's ADCs go abroad. Defining it as a China-market asset is in fact the most pragmatic.

Adebrelimab is a mirror reflecting the completely different value logic of large domestic pharma and biotech. A biotech betting on a molecule needs it either to dazzle or be out; but for a giant like Hengrui, a "good enough" fast follower, as long as it can be embedded in the commercial platform, serve as a portfolio foundation and give control over combinations, is enough to create solid returns — even if it is not number one in any lane.

Its biggest risk lies not in the clinic or in manufacturing, but in "being repeatedly beaten to market by peers" and "being marginalized within its own company's portfolio". Its biggest opportunity lies in whether Hengrui can, with discipline, fill in its accessibility, draw a clear boundary with camrelizumab, and fully exploit its combination value.

Perhaps the most accurate verdict on adebrelimab is: it doesn't need to stand out itself, but it makes Hengrui's portfolio more complete, more self-reliant and harder to replace. In an era when PD-L1s are no longer scarce, this "value of a foundation" is precisely the easiest to underestimate.